Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Drug Bonanza as Chi-Med, Eisai, Alexion Harvest Big Wins In China

Executive Summary

In a busy week for new drug approvals in China, the NMPA hands out nods for anticancers Elunate and Lenvima, rare disease treatment Soliris, and an additional indication for Humira, with Elunate being hailed by developer Chi-Med as the first fully "Made in China" novel oncology drug to receive unconditional approval.

Advertisement

Related Content

Oncology Dominates As China Approves Record 48 New Drugs In 2018
Eight For 8: Things You Need To Know About China Biopharma Regulation In 2018
Multinationals Eye Divesting Established Products In China Amid Fierce Competition, Shifting Focus
China Biotech Innovation Reaching Tipping Point?
Rare Diseases: What Makes China A Rising Star?
Chi-Med Roll Continues With Positive Fruquintinib Phase III Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel